HOX genes: potential candidates for the progression of laryngeal squamous cell carcinoma
- 373 Downloads
Laryngeal squamous cell carcinoma (LSCC) is a very aggressive cancer, considered to be a subtype of the head and neck squamous cell carcinoma (HNSCC). Despite significant advances in the understanding and treatment of cancer, prognosis of patients with LSCC has not improved recently. In the present study, we sought to understand better the genetic mechanisms underlying LSCC development. Thirty-two tumor samples were collected from patients undergoing surgical resection of LSCC. The samples were submitted to whole-genome cDNA microarray analysis aiming to identify genetic targets in LSCC. We also employed bioinformatic approaches to expand our findings using the TCGA database and further performed functional assays, using human HNSCC cell lines, to evaluate viability, cell proliferation, and cell migration after silencing of selected genes. Eight members of the homeobox gene family (HOX) were identified to be overexpressed in LSCC samples when compared to normal larynx tissue. Quantitative RT-PCR analysis validated the overexpression of HOX gene family members in LSCC. Receiver operating characteristic (ROC) statistical method curve showed that the expression level of seven members of HOX gene family can distinguish tumor from nontumor tissue. Correlation analysis of clinical and gene expression data revealed that HOXC8 and HOXD11 genes were associated with the differentiation degree of tumors and regional lymph node metastases, respectively. Additionally, siRNA assays confirmed that HOXC8, HOXD10, and HOXD11 genes might be critical for cell colony proliferation and cell migration. According to our findings, several members of the HOX genes were overexpressed in LSCC samples and seem to be required in biological processes involved in tumor development. This suggests that HOX genes might play a critical role in the physiopathology of LSCC tumors.
KeywordsLarynx squamous cell carcinoma Gene regulation HOX genes Cell migration
We thank Amélia Goes de Araújo and Patrícia Vianna Bonini Palma for the technical support at Flow Cytometry Core at National Institute of Science and Technology in Stem Cell and Cell Therapy for the technical support. We also thank Josane de Freitas Sousa for the critical review of the manuscript final version. This work was supported by grant no. 140427/2010-4, National Counsel of Technological and Scientific Development (CNPq); grant no. 559809/2009-3 CNPq/GENOPROT; and grant nos. 2012/00588-5 and #2013/08135-2, São Paulo Research Foundation (FAPESP).
Compliance with ethical standards
Ethics approval and consent to participate
This study was approved by the Ethics Committee of Ribeirão Preto Medical School, University of São Paulo (USP) (Proc. No. 9371/2003). All patients underwent surgical resection at the Head and Neck Surgery Division of the Department of Ophthalmology, Otorhinolaryngology and Head & Neck of Ribeirão Preto Medical School, USP, and an informed consent was obtained from patients before surgery.
Conflicts of interest
- 1.IARC – International Agency for Research on Cancer. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. https://www.iarc.fr. Accessed in 21 Jul 2015.Google Scholar
- 4.Silveira NJ, Varuzza L, Machado-Lima A, Lauretto MS, Pinheiro DG, Rodrigues RV, Severino P, Nobrega FG, Head and Neck Genome Project GENCAPO, Silva Jr WA, de B Pereira CA, Tajara EH. Searching for molecular markers in head and neck squamous cell carcinomas (HNSCC) by statistical and bioinformatic analysis of larynx-derived SAGE libraries. BMC Med Genet. 2008;11(1):56.Google Scholar
- 7.Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris III HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Cai J, Ma H, Huang F, Zhu D, Bi J, Ke Y, Zhang T. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World J Surg Oncol. 2013;28:11–306.Google Scholar
- 11.Plaça JR, Bueno RBL, Pinheiro DG, Panepucci RA, Araújo LF, Mamede RCM, Figueiredo DLA, Silva Jr WA. Gene expression analysis of laryngeal squamous cell carcinoma. Genomics Data. 2015;(5):9–12.Google Scholar
- 12.Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot T, Malta TM, Pagnotta SM, Castiglioni I, Ceccarelli M, Bontempi G, Noushmehr H. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;5(8):44–e71.Google Scholar
- 21.Wang L, Chen S, Xue M, Zhong J, Wang X, Gan L, Lam EK, Liu X, Zhang J, Zhou T, Yu J, Jin H, Si J. Homeobox D10 gene, a candidate tumor suppressor, is downregulated through promoter hypermethylation and associated with gastric carcinogenesis. Mol Med. 2012;9(18):389–400.Google Scholar
- 27.Rodini CO, Xavier FC, Paiva KB, De Souza Setúbal Destro MF, Moyses RA, Michaluarte P, Carvalho MB, Fukuyama EE, Head and Neck Project Gencapo, Tajara EH, Okamoto OK, Nunes FD. Homeobox gene expression profile indicates HOXA5 as a candidate prognostic marker in oral squamous cell carcinoma. Int J Oncol. 2012;40(4):1180–8.PubMedGoogle Scholar